Stockscreener 앱 받기
3.54
1.94%
-0.07
시장 영업 전:
3.54
전일 마감가:
$3.61
열려 있는:
$3.63
하루 거래량:
1.27M
Relative Volume:
0.40
시가총액:
$386.48M
수익:
-
순이익/손실:
$-223.12M
주가수익비율:
-1.7616
EPS:
-2.0095
순현금흐름:
$-190.49M
1주 성능:
+3.21%
1개월 성능:
-0.28%
6개월 성능:
+6.63%
1년 성능:
-54.90%
1일 변동 폭
$3.495
$3.67
1주일 범위
$3.31
$3.675
52주 변동 폭
$2.19
$7.77
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.54 | 386.48M | 0 | -223.12M | -190.49M | -2.0095 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-08-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-30 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-05-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-28 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2025-05-27 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
MSN Money - MSN
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Rocket Pharmaceuticals (RCKT) and Cullinan Management (CGEM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $9 - Moomoo
US premarket movers: Argan, Rocket Pharmaceuticals, Unity - MSN
LifeSci Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Rocket Pharmaceuticals sells priority review voucher for $180M - Investing.com UK
Leerink raises Rocket Pharmaceuticals stock price target on PRV sale By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Rocket Pharmaceuticals (RCKT) Enhances Financial Stability Throu - GuruFocus
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway - TipRanks
Rocket Pharmaceuticals to Sell Rare Pediatric Priority Review Voucher for $180 Million - TradingView
$180M PRV sale extends Rocket Pharmaceuticals (RCKT) cash runway to 2028 - Stock Titan
Rocket Pharmaceuticals sells priority review voucher for $180M By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher - The Joplin Globe
Rocket Pharmaceuticals sells priority review voucher for $180 million - StreetInsider
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - TMX Newsfile
Rocket Pharmaceuticals (RCKT) launches employee option exchange program - Stock Titan
Rocket Pharma wins FDA nod for gene therapy (update) - MSN
RCKTW Rocket quarterly earnings metrics not yet public as investors wait for management to share key operational updates.Real Trader Network - Xã Thanh Hà
RCKT (Rocket Pharmaceuticals Inc.) reports narrower Q4 2025 loss than analyst projections, shares tick up modestly after results.Earnings Analysis - Cổng thông tin điện tử tỉnh Tây Ninh
Lifesci Capital Has Pessimistic Outlook of RCKT Q1 Earnings - MarketBeat
Rocket Pharmaceuticals (RCKT) Stock Manual Trade (Grinds Lower) 2026-04-20Risk Reward Ratio - Cổng thông tin điện tử tỉnh Lào Cai
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
RCKT Technical Analysis | Trend, Signals & Chart Patterns | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals, Inc. Warrant (RCKTW) - Minichart
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Short Interest Update - MarketBeat
Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar - TipRanks
Needham Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Activity Recap: Is Rocket Pharmaceuticals Inc Equity Warrant a cyclical or defensive stock2026 News Drivers & Consistent Return Strategy Ideas - baoquankhu1.vn
Meme Stocks: Can Rocket Pharmaceuticals Inc expand into new markets2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Big Picture: Will Rocket Pharmaceuticals Inc benefit from sector rotationQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
RCKT stock dives despite gene therapy approval — Wall Street dismisses sell-off - MSN
Volume Report: Can Rocket Pharmaceuticals Inc deliver consistent EPS growth2026 Stock Rankings & AI Forecast Swing Trade Picks - baoquankhu1.vn
Aug Ideas: Is Rocket Pharmaceuticals Inc exposed to political risk2026 Winners & Losers & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving AverageHere's What Happened - MarketBeat
What is the growth rate of Rocket Pharmaceuticals (RCKT) Stock | Price at $3.56, Down 1.25%High Attention Stocks - Cổng thông tin điện tử tỉnh Lào Cai
What are the biggest risks for Rocket Pharmaceuticals (RCKT) Stock | Price at $3.48, Up 0.58%Investment Community Signals - Cổng thông tin điện tử Tỉnh Sơn La
[ARS] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Rocket Pharmaceuticals (NASDAQ: RCKT) seeks vote on director slate and option exchange - Stock Titan
Rally Mode: Is Rocket Pharmaceuticals Inc stock a good dividend stockPrice Action & Technical Confirmation Alerts - baoquankhu1.vn
Rocket gene therapy, among FDA’s March approvals, earns PRV - biocentury.com
[SC TO-C] ROCKET PHARMACEUTICALS, INC. Tender Offer Communication | RCKT SEC FilingForm SC TO-C - Stock Titan
FDA Grants Accelerated Approval to Rocket Pharma’s Gene Therapy Kresladi for LAD-I - The Indian Practitioner
Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring A Potential 138.80% Upside - DirectorsTalk Interviews
RCKTW SEC FilingsROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Rocket Pharmaceuticals Inc (9IP1.DU) valuation measures and financial statistics - Yahoo Finance UK
First Therapy Funded by California Taxpayer Dollars is Approved to Treat Rare Childhood Disorder - Noticias Newswire
Momentum Shift: What are Rocket Pharmaceuticals Incs growth levers2026 Action & Fast Entry High Yield Tips - baoquankhu1.vn
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):